Compare TECX & DSU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | TECX | DSU |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | United States |
| Employees | 60 | N/A |
| Industry | | Finance Companies |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 618.9M | 594.7M |
| IPO Year | N/A | 1998 |
| Metric | TECX | DSU |
|---|---|---|
| Price | $32.34 | $9.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $75.20 | N/A |
| AVG Volume (30 Days) | 150.1K | ★ 373.4K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.39 | $9.31 |
| 52 Week High | $39.53 | $10.64 |
| Indicator | TECX | DSU |
|---|---|---|
| Relative Strength Index (RSI) | 57.13 | 48.19 |
| Support Level | $27.30 | $9.33 |
| Resistance Level | $35.99 | $9.94 |
| Average True Range (ATR) | 1.50 | 0.06 |
| MACD | 0.16 | 0.02 |
| Stochastic Oscillator | 97.14 | 80.49 |
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Blackrock Debt Strategies Fund Inc is a closed-end management investment company. Its primary investment objective is to seek to provide current income by investing in a diversified portfolio of U.S. companies debt instruments, including senior and subordinated corporate loans, both secured and unsecured, which are rated in the lower rating categories of the established rating services or unrated debt instruments, which are in the judgment of the investment adviser of equivalent quality. The Fund may invest directly in debt instruments or synthetically through the use of derivatives. The Fund's secondary investment objective is to seek to provide capital appreciation.